OBJECTIVE: to assess the associations between nucleoside reverse transcriptase inhibitors (NRTIs) and change in lipid levels among a large cohort of HIV-infected patients in routine clinical care initiating their first potent antiretroviral regimen. DESIGN: longitudinal observational cohort study from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort. METHODS: we used generalized estimating equations to examine the association between NRTIs and lipids accounting for within-patient correlations between repeated measures and key clinical and demographic characteristics including other antiretroviral medications. RESULTS: among 2267 individuals who started their first antiretroviral regimen, tenofovir with emtricitabine or lamivudine was associated with lower levels for total cholesterol, low-density lipoprotein (LDL), triglycerides, non-high-density lipoprotein (HDL), and HDL, compared with other NRTI pairs in adjusted analyses. LDL levels were highest among patients receiving didanosine/lamivudine. Triglyceride levels were highest in stavudine/lamivudine users. HDL levels were highest among patients receiving didanosine/stavudine. Hepatitis C infection and younger age were also associated with lower lipid levels. CONCLUSION: we found clinically important heterogeneity within the NRTI class of antiretroviral medications regarding their effect on lipid levels over time. Although the lipid profile of tenofovir with emtricitabine or lamivudine appeared to be less pro-atherogenic in this large longitudinal study of HIV-infected patients in routine clinical care, there was no association with beneficial HDL levels. In general, the change in lipid levels associated with most antiretroviral agents, particularly those NRTI combinations currently in common use, are relatively modest. Additional studies are needed to understand the long-term implications of these findings on cardiovascular disease risk. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
OBJECTIVE: to assess the associations between nucleoside reverse transcriptase inhibitors (NRTIs) and change in lipid levels among a large cohort of HIV-infectedpatients in routine clinical care initiating their first potent antiretroviral regimen. DESIGN: longitudinal observational cohort study from the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort. METHODS: we used generalized estimating equations to examine the association between NRTIs and lipids accounting for within-patient correlations between repeated measures and key clinical and demographic characteristics including other antiretroviral medications. RESULTS: among 2267 individuals who started their first antiretroviral regimen, tenofovir with emtricitabine or lamivudine was associated with lower levels for total cholesterol, low-density lipoprotein (LDL), triglycerides, non-high-density lipoprotein (HDL), and HDL, compared with other NRTI pairs in adjusted analyses. LDL levels were highest among patients receiving didanosine/lamivudine. Triglyceride levels were highest in stavudine/lamivudine users. HDL levels were highest among patients receiving didanosine/stavudine. Hepatitis C infection and younger age were also associated with lower lipid levels. CONCLUSION: we found clinically important heterogeneity within the NRTI class of antiretroviral medications regarding their effect on lipid levels over time. Although the lipid profile of tenofovir with emtricitabine or lamivudine appeared to be less pro-atherogenic in this large longitudinal study of HIV-infectedpatients in routine clinical care, there was no association with beneficial HDL levels. In general, the change in lipid levels associated with most antiretroviral agents, particularly those NRTI combinations currently in common use, are relatively modest. Additional studies are needed to understand the long-term implications of these findings on cardiovascular disease risk. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: D Bollens; M Guiguet; P Tangre; L Rollinat; A Rachline; J L Meynard; P M Girard; P Benlian; M C Meyohas Journal: Infection Date: 2004-08 Impact factor: 3.553
Authors: Esteban Martínez; José A Arranz; Daniel Podzamczer; Montserrat Loncá; José Sanz; Patricia Barragán; Esteban Ribera; Hernando Knobel; Victor Roca; Félix Gutiérrez; José L Blanco; Josep Mallolas; Josep M Llibre; Bonaventura Clotet; David Dalmau; Ferran Segura; José R Arribas; Jaime Cosín; Pilar Barrufet; Esperanza Casas; Elena Ferrer; Adrià Curran; Alicia González; Judit Pich; Ana Cruceta; Joan A Arnaiz; José M Miró; José M Gatell Journal: J Acquir Immune Defic Syndr Date: 2009-07-01 Impact factor: 3.731
Authors: Adrian R Levy; Lawrence McCandless; P Richard Harrigan; Robert S Hogg; Greg Bondy; Uchenna H Iloeje; Jayanti Mukherjee; Julio S Montaner Journal: Lipids Health Dis Date: 2005-02-10 Impact factor: 3.876
Authors: Babafemi Taiwo; Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Susan L Koletar; Richard Moore; W Christopher Mathews; Heidi M Crane; Kenneth Mayer; Anne Zinski; James S Kahn; Joseph J Eron Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski Journal: World J Virol Date: 2015-05-12
Authors: Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Ana Carrero; Mónica García-Álvarez; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Cristina Diez; María Guzmán-Fulgencio; Amanda Fernández-Rodríguez; Salvador Resino Journal: AIDS Res Hum Retroviruses Date: 2014-10-29 Impact factor: 2.205
Authors: Elizabeth L Yanik; Sonia Napravnik; Patrick Ryscavage; Joseph J Eron; Susan L Koletar; Richard D Moore; Anne Zinski; Stephen R Cole; Peter Hunt; Heidi M Crane; James Kahn; William C Mathews; Kenneth H Mayer; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Emily S Brouwer; Sonia Napravnik; Joseph J Eron; Ross J Simpson; M Alan Brookhart; Brant Stalzer; Michael Vinikoor; Michelle Floris-Moore; Til Stürmer Journal: Med Care Date: 2015-06 Impact factor: 2.983